Research Article

Pharmacogenomic knowledge and awareness among diverse patients treated with angiotensin converting enzyme inhibitors

*Author for correspondence: Tel.: +1 650 498 4753;

E-mail Address: naikh@stanford.edu

https://orcid.org/0000-0002-5894-7390

Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Search for more papers by this author

Michelle Y O'Connor

Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Search for more papers by this author

Saskia C Sanderson

https://orcid.org/0000-0001-8427-724X

Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Search for more papers by this author

Nancy Pinnell

Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Search for more papers by this author

Mingshu Dong

Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Search for more papers by this author

Amy Wiegand

Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Search for more papers by this author

Aniwaa Owusu Obeng

https://orcid.org/0000-0002-1324-2573

Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Pharmacy Department, Mount Sinai Health System, New York, NY 10029, USA

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Search for more papers by this author

Noura S Abul-Husn

https://orcid.org/0000-0002-5179-1944

Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Search for more papers by this author

Stuart A Scott

**Author for correspondence: Tel.: +1 650 724 0973;

E-mail Address: sascott@stanford.edu

https://orcid.org/0000-0001-5720-1864

Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Search for more papers by this author

Published Online:6 Dec 2023https://doi.org/10.2217/pgs-2023-0191

View article

Abstract

We developed novel electronic phenotyping algorithms for the BioMe biobank data, which accurately identified angiotensin converting enzyme inhibitor (ACEi)-induced angioedema cases and controls. A survey was mailed to all 1075 patients and 91 were returned. Over a third reported that prescribing physicians had not discussed with them the concepts of interindividual drug response variability or adverse event risk, and 73% of patients were previously unaware of pharmacogenomics; however, most patients were interested in having pharmacogenomic testing. Moreover, 67% of patients indicated that pharmacogenomic testing would positively influence their medication compliance. In addition to identifying an innovative approach to define biobank cohorts for pharmacogenomic studies, these results indicate that patients are interested in pharmacogenomic testing, which could translate to improved adherence.

Keywords:

References

1. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 356(9230), 608–609 (2000).
Medline CASGoogle Scholar
2. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin. Pharmacol. Ther. 60(1), 8–13 (1996).
Medline CASGoogle Scholar
3. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 18(3), 171–188 (1998).
Medline CASGoogle Scholar
4. Duan QL, Nikpoor B, Dube MP et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am. J. Hum. Genet. 77(4), 617–626 (2005).
Medline CASGoogle Scholar
5. Scott SA, Nicoletti P. Novel Pharmacogenomic Locus Implicated in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. J. Am. Coll. Cardiol. 78(7), 710–712 (2021).
Medline CASGoogle Scholar
6. Ghouse J, Ahlberg G, Andreasen L et al. Association of Variants Near the Bradykinin Receptor B2 Gene With Angioedema in Patients Taking ACE Inhibitors. J. Am. Coll. Cardiol. 78(7), 696–709 (2021).
Medline CASGoogle Scholar
7. Haga SB, LaPointe NM. The potential impact of pharmacogenetic testing on medication adherence. The pharmacogenomics journal 13(6), 481–483 (2013).
Medline CASGoogle Scholar
8. Haga SB, O'Daniel JM, Tindall GM, Lipkus IR, Agans R. Survey of US public attitudes toward pharmacogenetic testing. The pharmacogenomics journal 12(3), 197–204 (2012).
Medline CASGoogle Scholar
9. Amin ME, Chewning BA, Wahdan AM. Sources of drug information for patients with chronic conditions in Alexandria, Egypt. The International journal of pharmacy practice 19(1), 13–20 (2011).
MedlineGoogle Scholar
10. Ascione FJ, Kirscht JP, Shimp LA. An assessment of different components of patient medication knowledge. Med. Care 24(11), 1018–1028 (1986).
Medline CASGoogle Scholar
11. Chan FW, Wong FY, So WY, Kung K, Wong CK. How much do elders with chronic conditions know about their medications? BMC geriatrics 13, 59 (2013).
MedlineGoogle Scholar
12. Field K, Ziebland S, McPherson A, Lehman R. ‘Can I come off the tablets now?’ A qualitative analysis of heart failure patients' understanding of their medication. Family practice 23(6), 624–630 (2006).
MedlineGoogle Scholar
13. Gottesman O, Scott SA, Ellis SB et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin. Pharmacol. Ther. 94(2), 214–217 (2013).
Medline CASGoogle Scholar
14. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin. Genet. 82(4), 388–394 (2012).
Medline CASGoogle Scholar
15. Johansen Taber KA, Dickinson BD. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmgenomics Pers. Med. 7, 145–162 (2014).
MedlineGoogle Scholar
16. Haga SB, Tindall G, O'Daniel JM. Public perspectives about pharmacogenetic testing and managing ancillary findings. Genet. Test Mol. Biomarkers 16(3), 193–197 (2012).
MedlineGoogle Scholar
17. Rahawi S, Naik H, Blake KV et al. Knowledge and attitudes on pharmacogenetics among pediatricians. J. Hum. Genet. 65(5), 437–444 (2020).
MedlineGoogle Scholar
18. Unertl KM, Jaffa H, Field JR, Price L, Peterson JF. Clinician Perspectives on Using Pharmacogenomics in Clinical Practice. Per. Med. 12(4), 339–347 (2015).
CASGoogle Scholar
19. Stanek EJ, Sanders CL, Taber KA et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450–458 (2012).
Medline CASGoogle Scholar
20. Haga SB, Mills R, Bosworth H. Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response. Patient Educ. Couns. 97(1), 10–15 (2014).
MedlineGoogle Scholar
21. Olson JE, Rohrer Vitek CR, Bell EJ et al. Participant-perceived understanding and perspectives on pharmacogenomics: the Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time). Genet. Med. 19(7), 819–825 (2017).
Medline CASGoogle Scholar
22. Lea DH, Kaphingst KA, Bowen D, Lipkus I, Hadley DW. Communicating genetic and genomic information: health literacy and numeracy considerations. Public Health Genomics 14(4-5), 279–289 (2011).
Medline CASGoogle Scholar
23. Saulsberry L, Danahey K, Borden BA et al. Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics. NPJ Genom. Med. 6(1), 90 (2021).
MedlineGoogle Scholar
24. McInnes G, Yee SW, Pershad Y, Altman RB. Genomewide Association Studies in Pharmacogenomics. Clin. Pharmacol. Ther. 110(3), 637–648 (2021).
MedlineGoogle Scholar
25. Motsinger-Reif AA, Jorgenson E, Relling MV et al. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet. Genomics 23(8), 383–394 (2013).
Medline CASGoogle Scholar
26. Yang SK, Hong M, Baek J et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet. 46(9), 1017–1020 (2014).
Medline CASGoogle Scholar
27. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4), 1022–1027 (2008).
Medline CASGoogle Scholar
28. Perera MA, Cavallari LH, Limdi NA et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382(9894), 790–796 (2013).
Medline CASGoogle Scholar
29. Kindmark A, Jawaid A, Harbron CG et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. The pharmacogenomics journal 8(3), 186–195 (2008).
Medline CASGoogle Scholar
30. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134–1143 (2011).
Medline CASGoogle Scholar

Vol. 24, No. 18

Metrics

Downloaded 56 times

History

Received 8 October 2023

Accepted 10 November 2023

Published online 6 December 2023

Published in print December 2023

Information

Keywords

Author contributions

H Naik, MY O'Connor, SC Sanderson, AO Obeng, NS Abul-Husn and SA Scott were responsible for study conception and design; H Naik, MY O'Connor, N Pinnell, M Dong, A K, AO Obeng, NS Abul-Husn and SA Scott were responsible for acquisition of data; H Naik, AO Obeng, and SA Scott were responsible for data analysis; and H Naik, MY O'Connor, SC Sanderson, N Pinnell, M Dong, A K, AO Obeng, NS Abul-Husn and SA Scott were responsible for drafting and/or revision of the manuscript.

Acknowledgments

The authors would like to thank the BioMe staff in the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai for their support.

Financial disclosure

SA Scott was supported in part by the NIH/NHGRI/NICHD/NIDA grant U24 HG010615. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

NS Abul-Husn is an employee and equity holder of 23 and Me and serves as a scientific advisory board member for Allelica. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study was deemed exempt by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai.

PDF download